Answers are grounded in this paper and cite their sources.
Background: Autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) have emerged as an independent biomarker for cardiovascular disease and mortality. However, their association with all-cause mortality in the community as well as their possible genetic determinants have not been studied. Objective: To determine whether anti-apoA-1 IgG: a) predict all-cause mortality in the general population, and b) are associated with single–nucleotide polymorphisms (SNPs) in a genome-wide association study (GWAS). Methods: Clinical, biological and genetic data from the population-based, prospective CoLaus study, including 5220 participants (mean age 52.6 years, 47.3% men) followed over a median duration of 5.6 years. The primary study outcome was all-cause mortality. Results: After multivariate adjustment, anti-apoA-1 IgG positivity independently predicted all-cause mortality: hazard ratio (HR)=1.54, 95% Confidence Interval (95%CI): (1.11-2.13), P=0.01. A dose-effect relationship was also observed, each standard deviation of logarithmically transformed anti-apoA-1 IgG being associated with a 15% increase in mortality risk: HR=1.15, 95%CI: (1.02-1.28), P=0.028. The GWAS yielded 9 SNPs belonging to the Fc receptor like-3 (FCRL3) gene that were significantly associated with anti-apoA-1 IgG levels, with the lead SNP (rs6427397, P=1.54×10-9) explaining 0.67% of anti-apoA-1 IgG level variation. Conclusion: Anti-apoA-1 IgG levels a) independently predict all-cause mortality in the general population and b) are linked to FCRL3, a susceptibility gene for numerous autoimmune diseases. Our findings indicate that preclinical autoimmunity to anti-apoA-1 IgG may represent a novel mortality risk factor.
No takes yet. Share an insight, caveat, or question.
Antiochos et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: